“Breakthrough” Means Breaking Down Bureaucracy
This article was originally published in RPM Report
Executive Summary
FDA’s Richard Pazdur has the oncology review team at FDA out on the cutting edge of “Breakthrough” reviews. He sees the key elements of making breakthrough work as cutting through layers of traditional processes and setting faster pathways for subsequent drugs.
You may also be interested in...
CDER Office of Product Quality Ready To Go: New Structure Sends Strong Signal To Industry
It took a while, but the Office of Pharmaceutical Quality is finally ready to begin operations. Biopharma companies should recognize the declaration of FDA’s priorities, and respond accordingly.
The Evolving Door? What Having A ‘Big Data’ Commissioner Might Mean For US FDA
Robert Califf’s nomination to return as FDA commissioner will raise protests about a ‘revolving door’ pathway between industry and agency. But, in this case, it may be more apt to talk about how Califf’s time outside FDA led to evolving views on the role of big data in drug regulation.
AAV Vector Consortia Address Quality Assays, Endpoints
Two outside groups aim to help CBER on gene therapy questions from ‘N of one’ to markers for hemophilia.